Introduction
According to the statistics, as one of the most malignant and lethal tumors, hepatocellular carcinoma (HCC) accounts for the majority of primary liver cancers (75% ~ 85%) [
1,
2]. Actually, approximately 910,000 new cases of primary liver cancer were diagnosed and caused 830,000 deaths globally in only 2020 worldwide. Unfortunately, the newly diagnosed liver cancer in China accounts for about half of all the cases (~ 410,000) [
2]. Despite great efforts have been paid to improve HCC diagnosis and treatments, the achievements are far from satisfactory and the poor prognosis of HCC patients is predictable [
3]. Therefore, exploring promising molecular targets that can serve as prognostic indicators for HCC patients remains a great challenge for humans, especially the Chinese.
Uncontrolled cell proliferation is one of the greatest features of all tumor cells, and there is abundant evidence that blocking cell proliferation or cell cycle processes has the potential to alleviate or cure tumors [
4,
5]. DNA replication is pivotal to tumor cell proliferation and is a fundamental process. The DBF4-dependent kinase (DDK) composed of CDC7 kinase and its regulatory subunit DBF4, which is required for CDC7 kinase activity, is a critical regulator of DNA replication by catalyzing MCM helicase (MCM2-7) (Fig.
1A) [
6,
7]. It has been reported that MCM family members can serve as prognostic biomarkers and MCM6 indicates adverse tumor features and poor outcomes and promotes S/G2 cell cycle progression in HCC [
8‐
10]. And the other DNA replication regulator complex cyclin-dependent kinases (CDKs) have plenty of roles in HCC development and can serve as therapeutic targets [
11‐
13]. While as the most critical regulator at DNA replication origin, the expression and potential role of DDK complex in HCC remain exclusive.
In this present study, we comprehensively analyzed the expression of DDK complex members (DBF4 and CDC7) and the relationship between their expression and clinical features based on HCC from our hospital and public databases (TCGA, GEO). The prognostic value of DDK complex members in HCC has been confirmed. Furtherly, the potential role of DDK complex members in cell cycle and DNA replication was further analyzed by Gene Set Enrichment Analysis (GSEA). These results may provide new clues for HCC precise diagnosis and therapy.
Methods
Data collection from public databases
Both the gene expression profiles of HCC patients and the corresponding clinical information were downloaded from the public TCGA HCC database (https:// portal.gdc.cancer.gov/repository) [
14], in which 50 paired normal liver tissues and 374 HCC tissues were included. The mRNA expression of DDK complex members was downloaded from three GEO databases (GSE25097, GSE54236, GSE64041) (
https://www.ncbi.nlm.nih.gov/geo/) [
15‐
17]. All these public data were processed (downloaded, sorted and de-duplicated) by R studio software (R version 3.6.3, Boston, MA, USA). The normalized expression of DDK members was analyzed by GraphPad Prism 9.0 (GraphPad, San Diego, CA, USA).
Kaplan–Meier plot for survival analysis
The survival analysis based on DDC complex expression and clinical information of HCC patients in TCGA HCC dataset was accomplished by online Web-Based Survival Analysis Tool (
http://kmplot.com/analysis/). The best cutoff used to define low and high expression for each analyzed gene is generated as described [
18]. Briefly, to find the best cutoff, they iterate over the input variable values from the lower quartile to the upper quartile and compute the Cox regression for each setting. The most significant cut-off value is used as the best cutoff to separate the input data into two groups.
Gene set enrichment analysis (GSEA)
GSEA as a computational method is frequently used to determine whether an a priori defined set of genes shows statistically significant, concordant differences between two biological states. We firstly sorted out the genes that were negatively or positively correlated with our target genes by pearson correlation analysis based on TCGA HCC expression files, and GSEA was then used to identify the potential biological functions of target genes. In this study, GSEA was automatically carried out by the online website tool LinkedOmics (
http://www.linkedomics.org/login.php) [
19]. Genes highly correlated with DBF4 and CDC7 (
P < 0.05) were subjected to further analysis (Enrichment analysis, KEGG pathway; Rank criteria,
P value; Minimum number of genes, 3; Simulations, 1000). Detailly, 1000 gene set permutations were performed for each analysis. The normalized enrichment score (NES) was calculated and the significantly enriched gene sets were screened. Then, the enrichment pathways with a normal
p-value < 0.05 and a false discovery rate (FDR) < 0.25 were selected.
Patients, tissue microarray and IHC staining
A cohort of 110 patients with confirmed HCC underwent tumor resection at West China Hospital of Sichuan University between 2016 and 2017. OS was defined as the time between initial surgery and death. The paraffin-embedded tumor samples were made into tissue microarray (TMA) cores (1 mm diameter). Immunohistochemistry (IHC) staining was then performed on the TMA slides with CDC7 antibody (ab229187, Abcam, Cambridge, UK), and the results were interpreted by three pathologists blinded to clinical information. The expression level of CDC7 was scored according to the signal intensity and distribution as previously described [
20]. Briefly, five 400 × -magnified areas were examined and assigned according to the following categories: 0, < 5%; 1, 5–25%; 2, 25–75%; 3, > 75%. The staining intensity was scored as follows: 1, weak; 2, moderate; and 3, intense. Tumor tissues with an IHC score of 0–3 were designated as low expression, and those with scores of 4–9 were designated as high expression. Classic core clinical features, such as age, AFP level, HBsAg, TNM stage, and tumor size, etc., were adopted to analyze the correlation of CDC7 with HCC. Approval for this study was granted by the Ethics Committee of the West China Hospital, Sichuan University, and each patient provided written informed consent.
Western blot assay
Fresh frozen tissues from HCC patients were collected and lysed with RIPA buffer according to the manufacturer’s instructions (Beyotime Biotechnology, Shanghai, China). For each lane, 50 μg protein was loaded for detecting DBF4 and CDC7 on different gels. Proteins were separated with SDS-PAGE and transferred to 0.45 μm PVDF membranes. Membranes were then blocked with PBS containing 0.05% tween and 5% non-fat milk. DBF4 antibody (ab124707, Abcam, Cambridge, UK) and CDC7 antibody (ab229187, Abcam, Cambridge, UK) were used to detect the protein level of DBF4 and CDC7, and GAPDH (ET1601-4, HuaBio, Hangzhou, China) was used as an internal control.
Statistical analysis
The DSS, PFS, RFS and OS of DDK complex members based on their expression and clinical data were automatically carried out by Kaplan–Meier Plotter (
http://kmplot.com/analysis) [
18]. All other statistical analyses were conducted by using the SPSS version 19.0 software program (SPSS Inc., Chicago, USA) or GraphPad Prism 7.0 (GraphPad, San Diego, CA, USA). The Kruskal–Wallis test, Wilcoxon rank test and logistic regression were used to analyze the relationship between DDK complex members and the clinical characteristics of HCC. Cox regression analysis was then used to compare the effects of CDC7 and clinical characteristics on OS and RFS. A
P value of less than 0.05 was considered statistically significant.
Discussion
DNA replication, as one of the most fundamental processes for tumor cell proliferation, is sophisticated and finely regulated. Substantial evidence has proved that key regulators of DNA replication play critical roles in cell proliferation and are potential therapeutic targets for cancers [
21,
22]. DNA replication requires the activities of CDKs and DDK complex, both of which are essential for DNA replication, chromosome segregation, centromeric heterochromatin formation, and genome maintenance of mitotic cells [
23‐
25]. The role of CDKs, especially CDK4/CDK6 complex, in HCC development has been well illustrated, and its specific inhibitor has been adopted for HCC treatment [
11‐
13]. However, the role of DDK complex in HCC remains unknown.
In this present study, we firstly comprehensively analyzed the expression of DBF4 and CDC7 in HCC patients, and found both of them were highly expressed in HCC tumor tissues. As a whole complex member and elevated in most cancer types, DBF4 and CDC7 were found positively correlated with each other in 26 TCGA cancer types, especially in HCC. In addition, their expression was found higher in advanced HCC patients with higher clinical stages and grades. Patients with higher DBF4 or CDC7 expression were more likely to have a poor prognosis. Finally, according to our HCC cohort, we found the expression of CDC7 was highly correlated with tumor size and TNM stage of HCC patients, and patients with higher CDC7 expression had a shorter overall survival.
In an unperturbed cell cycle, the DDK complex binds to and phosphorylates its essential target—the MCM2-7 ring to initiate DNA replication, which leads to gate opening between MCM2 and MCM5, allowing extrusion of single-stranded DNA generated by origin melting, which is critical for DNA replication. It has been reported that MCM family members may play important roles in HCC development and can serve as prognostic biomarkers in HCC [
7‐
9], the function of which is largely dependent on DDK complex. Checkpoint is activated when cells suffer DNA damage or are depleted of dNTPs, in which cases DDK complex is phosphorylated by radiation-sensitive 53 (Rad53) kinase, causing its dissociation from chromatin [
26,
27]. Therefore, the highly expressed DDK complex members in HCC may facilitate and accelerate tumor cell proliferation. This speculation was further confirmed by pearson and GSEA analysis, the genes highly associated with CDC7 and DBF4 are enriched in cell cycle, DNA replication and microRNA in cancer pathways.
Similar to CDKs, the DDK complex may serve as potential therapeutical target. Before that more studies are needed to explore the molecular mechanism underlying the elevation of their expression (upstream regulator, methylation, mutation or amplification, etc.) and the consequences caused by their ablation or silence, which may provide new insights and therapeutic cues for HCC patients.
Conclusions
In summary, we performed a comprehensive analysis of the expression and potential role of DDK complex in HCC. Like most oncogenes, high expression of DBF4 and CDC7 is associated with poor prognosis, and both may be potential independent prognostic factors for HCC patients.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.